Everest Medicines Announces that Licensing Partner LIB Therapeutics has Received U.S. FDA Approval of LEROCHOL™ (lerodalcibep-liga) for Adults with Elevated LDL Cholesterol
SHANGHAI, Dec. 17, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today...
Insilico Medicine and TaiGen Achieves License Agreement to Develop and Commercialize AI-driven PHD Inhibitor for Anemia of Chronic Kidney Disease (CKD)
Insilico Medicine has licensed TaiGen Biotechnology exclusive rights in the Greater China area to develop, commercialize, and sub-license ISM4808, an AI-driven potential best-in-class oral PHD inhibitor with IND clearance granted in 2023. The...
Solace and NetComm Commercialize World's First Wirelessly Powered, Window-Mounted 5G CPE
MOUNT PEARL, NL and SYDNEY, Dec. 11, 2025 /PRNewswire/ -- Solace Power Inc. ("Solace") and NetComm Wireless ("NetComm") today announced a strategic partnership to co-develop and commercialize the world's first wirelessly powered, window-mounted...
Kelun-Biotech and Crescent Biopharma Announce Strategic Partnership to Develop and Commercialize Novel Oncology Therapeutics
Companies to advance CR-001, a PD-1 x VEGF bispecific antibody, and SKB105, an integrin beta-6-directed antibody-drug conjugate (ADC), in global markets and China Collaboration designed to accelerate and expand the development of synergistic...
Simcere's IL-2 Mutant Fusion Protein SIM0278 Entered Phase II Clinical Trial Stage
NANJING, China, Nov. 10, 2025 /PRNewswire/ -- Simcere Pharmaceutical Group (2096.HK) announced that its regulatory T cells（Treg）-preferential IL-2 mutant Fc fusion protein (IL-2 mu-Fc), SIM0278, has officially entered a Phase II clinical study in...
Alphamab Oncology Announces Biparatopic HER2-targeting ADC JSKN003 Was Granted Fast Track Designation by FDA for the Treatment of PROC
SUZHOU, China, Oct. 28, 2025 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that the biparatopic HER2-targeting antibody-drug conjugate (ADC) JSKN003 has been granted Fast Track Designation (FTD) by the U.S. Food and Drug...
SK Biopharmaceuticals Launches Joint Venture with Eurofarma for AI-based Epilepsy Management Platform
SK Biopharmaceuticals forms a joint venture, Mentis Care, to develop an integrated epilepsy care ecosystem through AI-driven platform commercialization. SEOUL, South Korea, Oct. 21, 2025 /PRNewswire/ -- SK Biopharmaceuticals, Co., Ltd., a biotech...
A.D.A.M. Innovations and SOPHiA GENETICS partner to advance liquid biopsy testing and companion diagnostics for precision oncology in Japan
ROLLE, Switzerland and TOKYO, Oct. 16, 2025 /PRNewswire/ -- A.D.A.M. Innovations, Japan's leading private genetic testing company, and SOPHiA GENETICS (Nasdaq: SOPH), an AI technology company pioneering data-driven medicine, today announced at ESMO...
Canopus Networks & UNSW Sydney Secure $433K Grant from Australian Government to Commercialize AI-Powered Cloud Security
Australian Government backs Canopus Networks and UNSW on AI Cyber Defense for SMEs SYDNEY, March 24, 2025 /PRNewswire/ -- Canopus Networks and UNSW Sydney have secured a $433K grant from the Australian Government under the Australian Economic...
BenQ Medical Technology and Brain Navi Align Partnership to Advance Neurosurgical Robotics in China
Enhancing Precision and Innovation in Neurosurgical Robotics Across China ZHUBEI, March 20, 2025 /PRNewswire/ -- Brain Navi Biotechnology, a leading innovator in neurosurgical robotics, has announced a strategic partnership with BenQ Medical...